Specifically, pancreatic lipase (PL) has been used on numerous occasions, both immobilized and in solution, as an important target for screening compounds that inhibit its activity, which could act as potential anti-obesity drugs. The gene discussed is PNLIP; the disease is obesity due to melanocortin 4 receptor deficiency.